-
Enliven Therapeutics, Inc (ELVN) Tops Q2 EPS by 6c
-
Enliven Therapeutics (ELVN) PT Raised to $48 at H.C. Wainwright
-
TD Cowen Names Enliven Therapeutics (ELVN) Best Smidcap Idea
-
Goldman Sachs Starts Enliven Therapeutics (ELVN) at Buy
-
Enliven Therapeutics, Inc (ELVN) Prices 8.39M Share Offering at $19.66/sh
-
Enliven Therapeutics, Inc (ELVN) Announces Proposed $200M Share Offering
-
Enliven Therapeutics, Inc (ELVN) Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001
-
Enliven Therapeutics (ELVN) PT Raised to $41 at Mizuho
-
Enliven Therapeutics (ELVN) PT Raised to $45 at BTIG, 'We increase our PoS for the ELVN-001 program and remove ELVN-002 from our model for HER2+ solid tumors'
-
Enliven Therapeutics (ELVN) PT Raised to $40 at H.C. Wainwright
-
Enliven Therapeutics, Inc (ELVN) Misses Q1 EPS by 7c
-
Enliven Therapeutics, Inc (ELVN) announces updated positive data from Phase 1 ELVN-001 trial
-
Enliven Therapeutics, Inc (ELVN) Tops Q4 EPS by 6c
-
BTIG Starts Enliven Therapeutics (ELVN) at Buy
-
Clear Street Starts Enliven Therapeutics (ELVN) at Buy, Top Pick
-
Enliven Therapeutics (ELVN) PT Raised to $40 at Baird
-
Enliven Therapeutics, Inc (ELVN) Tops Q3 EPS by 3c
-
Jones Trading Starts Enliven Therapeutics (ELVN) at Buy
-
H.C. Wainwright Reiterates Buy Rating on Enliven Therapeutics (ELVN)
-
Mizuho Reiterates Outperform Rating on Enliven Therapeutics (ELVN)
-
TD Cowen Reiterates Buy Rating on Enliven Therapeutics (ELVN)
-
Mizuho Reiterates Outperform Rating on Enliven Therapeutics (ELVN)
-
H.C. Wainwright Starts Enliven Therapeutics (ELVN) at Buy
-
Enliven Therapeutics (ELVN) PT Raised to $39 at Mizuho
-
TD Cowen Reiterates Buy Rating on Enliven Therapeutics (ELVN)
-
Baird Starts Enliven Therapeutics (ELVN) at Outperform

